AIM - AIM Immunotech shares jump after subsidiary nabs Orphan Medicinal Product status from EC

AIM ImmunoTech (AIM) company NV Hemispherx Biopharma Europe, has received formal notification from the European Commission ((EC)) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.Shares of the company were trading up nearly 16% premarket.Medications that have been designated as Orphan products by the European Medicines Agency ((EMA)), once commercially approved in the European Union ((EU)), receive benefits including up to ten years of protection from market competition from similar medicines with similar active component and indication for use that are not shown to be clinically superior.An estimated 466K people died of pancreatic cancer worldwide in 2020, according to the World Health Organization.

For further details see:

AIM Immunotech shares jump after subsidiary nabs Orphan Medicinal Product status from EC